Product
Lutetium Oxodotreotide
1 clinical trial
1 indication
Clinical trial
Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.Status: Recruiting, Estimated PCD: 2026-12-01